Breaking News
LAST CHANCE for Cyber Monday SALE: Up to 54% off InvestingPro! Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Catalent Acquires Gene Therapy Leader Paragon Bioservices

By Zacks Investment ResearchStock MarketsMay 21, 2019 08:52AM ET
Catalent Acquires Gene Therapy Leader Paragon Bioservices
By Zacks Investment Research   |  May 21, 2019 08:52AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Catalent, Inc. (NYSE:CTLT) recently announced that it has closed the $1.2-billion acquisition of Paragon Bioservices, Inc. — a leading viral vector development and manufacturing partner for gene therapies.

Shares of Catalent have surged 45.5% year to date compared with the industry’s growth of 4.7%.

With this acquisition, Catalent will add to its portfolio Paragon’s specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used vector to deliver DNA to cells. This positions Catalent to capitalize on strong industry tailwinds in the potentially $40-billion addressable market for gene therapies. Catalent will also add Paragon’s unique and differentiated scientific, development, and manufacturing capabilities, which will enhance the biologics business of the former as well as end-to-end integrated biopharmaceutical solutions for customers.

Paragon has GMP manufacturing projects underway with more than half of the top 40 leading gene therapy developers worldwide. It also opened its new, state-of-the-art commercial manufacturing center near the Baltimore-Washington International (BWI) airport, which is equipped with several 500-liter and 2,000-liter single-use bioreactors for clinical through commercial material production. Catalent is committed to the resource dedication for Paragon’s customers, and maintaining a flexible and reliable development and manufacturing partnership for its clients.

The above-mentioned transaction will enable Catalent to achieve its next stage of development as well as expand the firm’s capabilities and platform for the benefit of customers and their patients. By working with Paragon's talented team and world-class customers, Catalent will be able to complete the significant ongoing investments into expanded state-of-the-art facilities and deliver revolutionary, lifesaving treatments to patients.

Also, in connection with the acquisition of Paragon, Catalent has completed the issuance of $650 million of a new series of convertible preferred stock.

Zacks Rank & Stock to Consider

Currently, Catalent carries a Zacks Rank #3 (Hold).

A better-ranked stock in the same space is Eisai Co. (OTC:ESALY) , Recro Pharma Inc. (NASDAQ:REPH) and Evotec AG (OTC:EVTCY) . All of these sport a Zacks Rank #1 (Strong Buy), at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Eisai’s earnings per share estimates have moved up from $1.91 to $1.95 for 2019 and from $1.93 to $2.02 for 2020, in the past 60 days.

Recro Pharma’s loss per share estimates have narrowed from $3.73 to 54 cents for 2019 and from a loss $1.51 to a profit of 6 cents for 2020, in the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters, the average beat being 41.88%.

Evotec’s earnings per share estimates have moved up from 86 cents to 90 cents for 2019 in 60 days’ time.

Will you retire a millionaire?

One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”

Click to get it free >>.

Catalent, Inc. (CTLT): Free Stock Analysis Report

Eisai Co. (ESALY): Free Stock Analysis Report

Recro Pharma, Inc. (REPH): Free Stock Analysis Report

Evotec AG (EVTCY): Free Stock Analysis Report

Original post

Zacks Investment Research
Catalent Acquires Gene Therapy Leader Paragon Bioservices

Related Articles

Catalent Acquires Gene Therapy Leader Paragon Bioservices

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email